Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 6/20 | 0.64 |
| ▸ | APLNR | P35414 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575246 | 0.86 | ALDH1A1 (0.55) | PYCR1APLNRALDH1A1MAOBMAOA | |
| SCHEMBL27210386 | 0.80 | PYCR1 (0.72) | PYCR1APLNRALDH1A1MAOBMAOA | |
| SCHEMBL29235425 | 0.78 | PYCR1 (1.00) | PYCR1ALDH1A1MAOBMAOALMNA | |
| SCHEMBL15662442 | 0.71 | PYCR1 (0.70) | PYCR1APLNRALDH1A1MAOBLMNA | |
| SCHEMBL4739963 | 0.70 | PYCR1 (0.64) | PYCR1APLNRALDH1A1LMNAMAPT | |
| SCHEMBL11411730 | 0.70 | — | — | |
| SCHEMBL4137602 | 0.69 | PYCR1 (0.56) | PYCR1ALDH1A1MAOBMAPTIDO1 | |
| SCHEMBL5270803 | 0.68 | APLNR (0.59) | PYCR1APLNRALDH1A1LMNAMAPT | |
| SCHEMBL12049800 | 0.68 | APLNR (0.59) | PYCR1APLNRALDH1A1LMNAMAPT | |
| SCHEMBL3803477 | 0.67 | IDO1 (0.52) | PYCR1MAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140931-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4288436-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116940573-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140931-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | CYP2C19, CYP3A7, CYP11B2 | PYCR1 1475/4885APLNR 4346/4885ALDH1A1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.